Frontline DNA-Repair Inhibition as Maintenance in High-Risk Ovarian Carcinoma

• Dr. Latha Kiran Krishna Rajendran

  Author

Relapse after surgery and platinum-based chemotherapy remains common in newly diagnosed advanced epithelial ovarian carcinoma, underscoring the need for effective post-chemotherapy strategies. This narrative review evaluated the published SOLO1 trial, which assessed an oral, targeted inhibitor of tumor DNA-repair signaling (olaparib) as single-agent maintenance in women with newly diagnosed advanced ovarian, primary peritoneal, or fallopian-tube cancer with a BRCA1/2 mutation who had responded to platinum-based chemotherapy. The primary objective was prolongation of progression-free survival, with key secondary endpoints including time to subsequent therapy, a second progression-based measure, health-related quality of life, and safety. In the published trial, maintenance therapy produced a marked and durable delay in radiographic progression versus placebo, with consistent advantages across prespecified secondary outcomes and sustained separation of event-free survival curves over prolonged follow-up. Treatment was generally manageable, with class-consistent gastrointestinal, fatigue, and hematologic adverse events addressed by dose interruption or reduction, and without emergent safety signals; patient-reported quality of life was maintained. These findings support biomarker-guided inhibition of DNA-repair pathways as a standard maintenance approach in frontline management of newly diagnosed advanced BRCA-mutated ovarian, primary peritoneal, or fallopian-tube cancer responding to platinum, reinforcing the role of precision therapeutics in extending remission without compromising quality of life. All reported patient numbers, efficacy outcomes, safety outcomes, subgroup findings, and health-related quality-of-life results are derived from the cited published clinical-trial reports.

• PDF

Copyright (c) 2026 International Journal of Clinical Research and Medical Sciences

This work is licensed under a Creative Commons Attribution 4.0 International License.